Hansoh Pharmaceutical Group Company akcijos akcijų analizė | Akcijų kaina | Naujienos | 3692.HK | KYG549581067 | A2PLRC

Data	Hansoh Pharmaceutical Group Company Pajamos	Hansoh Pharmaceutical Group Company EBIT	Hansoh Pharmaceutical Group Company Pelnas
2029e	17,61 mlrd. undefined	0 undefined	0 undefined
2028e	16,25 mlrd. undefined	5,61 mlrd. undefined	0 undefined
2027e	14,91 mlrd. undefined	5,25 mlrd. undefined	0 undefined
2026e	14,13 mlrd. undefined	4,39 mlrd. undefined	4,28 mlrd. undefined
2025e	12,65 mlrd. undefined	3,89 mlrd. undefined	3,77 mlrd. undefined
2024e	12,10 mlrd. undefined	3,87 mlrd. undefined	3,77 mlrd. undefined
2023	10,10 mlrd. undefined	2,65 mlrd. undefined	3,28 mlrd. undefined
2022	9,38 mlrd. undefined	2,57 mlrd. undefined	2,58 mlrd. undefined
2021	9,94 mlrd. undefined	2,96 mlrd. undefined	2,71 mlrd. undefined
2020	8,69 mlrd. undefined	2,78 mlrd. undefined	2,57 mlrd. undefined
2019	8,68 mlrd. undefined	2,80 mlrd. undefined	2,56 mlrd. undefined
2018	7,72 mlrd. undefined	2,26 mlrd. undefined	1,90 mlrd. undefined
2017	6,19 mlrd. undefined	1,91 mlrd. undefined	1,60 mlrd. undefined
2016	5,43 mlrd. undefined	1,79 mlrd. undefined	1,48 mlrd. undefined

	Pajamos	EBIT	Pelnas
2016	5,43 mlrd. CNY	1,79 mlrd. CNY	1,48 mlrd. CNY
2017	6,19 mlrd. CNY	1,91 mlrd. CNY	1,60 mlrd. CNY
2018	7,72 mlrd. CNY	2,26 mlrd. CNY	1,90 mlrd. CNY
2019	8,68 mlrd. CNY	2,80 mlrd. CNY	2,56 mlrd. CNY
2020	8,69 mlrd. CNY	2,78 mlrd. CNY	2,57 mlrd. CNY
2021	9,94 mlrd. CNY	2,96 mlrd. CNY	2,71 mlrd. CNY
2022	9,38 mlrd. CNY	2,57 mlrd. CNY	2,58 mlrd. CNY
2023	10,10 mlrd. CNY	2,65 mlrd. CNY	3,28 mlrd. CNY
2024e	12,10 mlrd. CNY	3,87 mlrd. CNY	3,77 mlrd. CNY
2025e	12,65 mlrd. CNY	3,89 mlrd. CNY	3,77 mlrd. CNY
2026e	14,13 mlrd. CNY	4,39 mlrd. CNY	4,28 mlrd. CNY
2027e	14,91 mlrd. CNY	5,25 mlrd. CNY	0 CNY
2028e	16,25 mlrd. CNY	5,61 mlrd. CNY	0 CNY
2029e	17,61 mlrd. CNY	0 CNY	0 CNY

2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e
5,43	6,19	7,72	8,68	8,69	9,94	9,38	10,10	12,10	12,65	14,13	14,91	16,25	17,61
-	13,86	24,85	12,43	0,09	14,33	−5,57	7,68	19,80	4,48	11,78	5,51	8,98	8,38
92,69	92,64	92,19	91,60	90,75	91,23	90,73	89,79	-	-	-	-	-	-
5,04	5,73	7,12	7,95	7,89	9,06	8,51	9,07	0	0	0	0	0	0
1,79	1,91	2,26	2,80	2,78	2,96	2,57	2,65	3,87	3,89	4,39	5,25	5,61	0
32,90	30,95	29,20	32,22	32,03	29,78	27,34	26,19	31,96	30,77	31,03	35,17	34,49	-
1,48	1,60	1,90	2,56	2,57	2,71	2,58	3,28	3,77	3,77	4,28	0	0	0
-	8,06	19,31	34,31	0,47	5,61	−4,76	26,87	14,89	0,24	13,51	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-
5,16	5,16	5,16	5,48	5,88	6,00	5,93	6,02	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-

2016	2017	2018	2019	2020	2021	2022
1,80	1,93	2,31	3,00	3,10	3,30	2,95
119,00	135,00	156,00	201,00	233,00	278,00	344,00
0	0	0	0	0	0	0
−669,00	−644,00	−350,00	291,00	−806,00	−747,00	−629,00
−6,00	−21,00	−43,00	−163,00	−134,00	−253,00	77,00
3,00	0	0	0	0	0	0
311,00	231,00	306,00	541,00	590,00	319,00	324,00
1,25	1,40	2,07	3,33	2,39	2,58	2,74
−238,00	−256,00	−381,00	−592,00	−1 427,00	−460,00	−272,00
829,00	−614,00	−1 388,00	−7 075,00	−2 874,00	−2 259,00	−5 935,00
1,07	−0,36	−1,01	−6,48	−1,45	−1,80	−5,66
0	0	0	0	0	0	0
−0,05	0	0	−0,04	−0,01	3,84	−0,04
1,30	0	0	9,53	3,17	−0,04	−0,06
−2,05	−0,73	0	7,99	−1,04	3,42	−0,82
−3 301,00	−730,00	-	-	-	-	-
0	0	0	−1 500,00	−4 200,00	−380,00	−712,00
0,05	0,06	0,70	4,38	−2,28	3,66	−4,05
1 007,58	1 145,91	1 690,85	2 737,21	962,83	2 117,03	2 468,38
0	0	0	0	0	0	0

Hansoh Pharmaceutical Group Company Bruto marža	Hansoh Pharmaceutical Group Company Pelnas-martža	Hansoh Pharmaceutical Group Company EBIT marža	Hansoh Pharmaceutical Group Company Pelnas-martža
2029e	89,78 %	0 %	0 %
2028e	89,78 %	34,49 %	0 %
2027e	89,78 %	35,17 %	0 %
2026e	89,78 %	31,03 %	30,31 %
2025e	89,78 %	30,77 %	29,85 %
2024e	89,78 %	31,96 %	31,11 %
2023	89,78 %	26,19 %	32,44 %
2022	90,73 %	27,34 %	27,54 %
2021	91,24 %	29,79 %	27,31 %
2020	90,76 %	32,03 %	29,56 %
2019	91,60 %	32,22 %	29,45 %
2018	92,19 %	29,21 %	24,64 %
2017	92,64 %	30,95 %	25,79 %
2016	92,69 %	32,89 %	27,17 %

	Bruto marža	EBIT marža	Pelnas-martža
2016	92,69 %	32,89 %	27,17 %
2017	92,64 %	30,95 %	25,79 %
2018	92,19 %	29,21 %	24,64 %
2019	91,60 %	32,22 %	29,45 %
2020	90,76 %	32,03 %	29,56 %
2021	91,24 %	29,79 %	27,31 %
2022	90,73 %	27,34 %	27,54 %
2023	89,78 %	26,19 %	32,44 %
2024e	89,78 %	31,96 %	31,11 %
2025e	89,78 %	30,77 %	29,85 %
2026e	89,78 %	31,03 %	30,31 %
2027e	89,78 %	35,17 %	0 %
2028e	89,78 %	34,49 %	0 %
2029e	89,78 %	0 %	0 %

Data	Hansoh Pharmaceutical Group Company Pardavimai vienai akcijai	Hansoh Pharmaceutical Group Company EBIT vienai akcijai	Hansoh Pharmaceutical Group Company Pelnas vienai akcijai
2029e	2,97 undefined	0 undefined	0 undefined
2028e	2,74 undefined	0 undefined	0 undefined
2027e	2,52 undefined	0 undefined	0 undefined
2026e	2,39 undefined	0 undefined	0,72 undefined
2025e	2,13 undefined	0 undefined	0,64 undefined
2024e	2,04 undefined	0 undefined	0,64 undefined
2023	1,68 undefined	0,44 undefined	0,54 undefined
2022	1,58 undefined	0,43 undefined	0,44 undefined
2021	1,66 undefined	0,49 undefined	0,45 undefined
2020	1,48 undefined	0,47 undefined	0,44 undefined
2019	1,59 undefined	0,51 undefined	0,47 undefined
2018	1,50 undefined	0,44 undefined	0,37 undefined
2017	1,20 undefined	0,37 undefined	0,31 undefined
2016	1,05 undefined	0,35 undefined	0,29 undefined

	Pardavimai vienai akcijai	EBIT vienai akcijai	Pelnas vienai akcijai
2016	1,05 CNY	0,35 CNY	0,29 CNY
2017	1,20 CNY	0,37 CNY	0,31 CNY
2018	1,50 CNY	0,44 CNY	0,37 CNY
2019	1,59 CNY	0,51 CNY	0,47 CNY
2020	1,48 CNY	0,47 CNY	0,44 CNY
2021	1,66 CNY	0,49 CNY	0,45 CNY
2022	1,58 CNY	0,43 CNY	0,44 CNY
2023	1,68 CNY	0,44 CNY	0,54 CNY
2024e	2,04 CNY	0 CNY	0,64 CNY
2025e	2,13 CNY	0 CNY	0,64 CNY
2026e	2,39 CNY	0 CNY	0,72 CNY
2027e	2,52 CNY	0 CNY	0 CNY
2028e	2,74 CNY	0 CNY	0 CNY
2029e	2,97 CNY	0 CNY	0 CNY

	Akcijų skaičius
2016	5,16 mlrd. Aktien
2017	5,16 mlrd. Aktien
2018	5,16 mlrd. Aktien
2019	5,48 mlrd. Aktien
2020	5,88 mlrd. Aktien
2021	6,00 mlrd. Aktien
2022	5,93 mlrd. Aktien
2023	6,02 mlrd. Aktien
2024e	6,02 mlrd. Aktien
2025e	6,02 mlrd. Aktien
2026e	6,02 mlrd. Aktien
2027e	6,02 mlrd. Aktien
2028e	6,02 mlrd. Aktien
2029e	6,02 mlrd. Aktien

Data	Hansoh Pharmaceutical Group Company Dividendas
2029e	0,20 undefined
2028e	0,20 undefined
2027e	0,20 undefined
2026e	0,21 undefined
2025e	0,20 undefined
2024e	0,21 undefined
2023	0,19 undefined
2022	0,23 undefined
2021	0,08 undefined

	Dividendas	Dividenda (įvertinimas)
2016	0 CNY	0 CNY
2017	0 CNY	0 CNY
2018	0 CNY	0 CNY
2019	0 CNY	0 CNY
2020	0 CNY	0 CNY
2021	0,08 CNY	0 CNY
2022	0,23 CNY	0 CNY
2023	0,19 CNY	0 CNY
2024e	0 CNY	0,21 CNY
2025e	0 CNY	0,20 CNY
2026e	0 CNY	0,21 CNY
2027e	0 CNY	0,20 CNY
2028e	0 CNY	0,20 CNY
2029e	0 CNY	0,20 CNY

Data	Hansoh Pharmaceutical Group Company Išmokėjimo santykis
2029e	37,80 %
2028e	38,60 %
2027e	37,72 %
2026e	37,07 %
2025e	41,00 %
2024e	35,10 %
2023	35,10 %
2022	52,78 %
2021	17,43 %
2020	35,10 %
2019	35,10 %
2018	35,10 %
2017	35,10 %
2016	35,10 %

	Išmokėjimo santykis
2016	35,10 %
2017	35,10 %
2018	35,10 %
2019	35,10 %
2020	35,10 %
2021	17,43 %
2022	52,78 %
2023	35,10 %
2024e	35,10 %
2025e	41,00 %
2026e	37,07 %
2027e	37,72 %
2028e	38,60 %
2029e	37,80 %

%	Pavadinimas	Akcijos	Pokytis	Data
65,81 %	Zhong (Huijuan)	3 900 000 000	0	2023-04-29
16,03 %	Cen (Junda)	950 000 000	0	2023-09-01
1,92 %	Fidelity Management & Research Company LLC	113 965 695	11 777 867	2024-02-29
0,53 %	The Vanguard Group, Inc.	31 343 444	−360 000	2024-03-31
0,50 %	FIL Investment Management (Hong Kong) Limited	29 735 359	−1 757 555	2024-02-29
0,46 %	UBS Asset Management (Hong Kong) Limited	27 523 481	−22 000	2023-12-31
0,41 %	BlackRock Institutional Trust Company, N.A.	24 052 609	−250 000	2024-03-31
0,35 %	Federated Hermes International	20 700 249	243 568	2023-12-31
0,34 %	FIL Investment Management (Singapore) Ltd.	20 295 197	−2 810 023	2024-02-29
0,32 %	Bosera Asset Management Co., Ltd.	19 032 000	4 672 000	2023-12-31
0,30 %	Hang Seng Investment Management Ltd.	17 848 002	−239 454	2024-03-31
0,28 %	Fidelity International	16 361 328	−867 816	2024-02-29
0,26 %	BlackRock Advisors (UK) Limited	15 344 000	446 000	2024-03-31
0,24 %	GF Fund Management Co., Ltd.	14 358 000	8 792 000	2023-12-31
0,23 %	State Street Global Advisors Asia Ltd.	13 365 578	52 380	2023-10-31
0,22 %	APG Asset Management N.V.	13 197 027	12 046 080	2023-09-30
0,19 %	ZhongGeng Fund Management Co., Ltd.	11 328 000	6 758 000	2023-06-30
0,18 %	Norges Bank Investment Management (NBIM)	10 786 186	−3 033 404	2023-12-31
0,15 %	China Asset Management Co., Ltd.	8 700 000	3 414 156	2023-12-31
0,11 %	E Fund Management Co. Ltd.	6 348 000	4 970 000	2023-12-31
0,09 %	Geode Capital Management, L.L.C.	5 530 000	298 000	2024-02-29
0,08 %	HuaAn Fund Management Co., Ltd.	4 834 000	4 812 000	2023-12-31
0,08 %	Dimensional Fund Advisors, L.P.	4 750 000	0	2024-03-31
0,08 %	Pictet Asset Management Ltd.	4 480 000	−86 000	2023-12-31
0,06 %	Amundi Asset Management, SAS	3 766 000	160 000	2024-03-31
0,06 %	Northern Trust Global Investments Limited	3 419 084	0	2024-02-29
0,06 %	UBS Asset Management (UK) Ltd.	3 324 970	−84 000	2024-03-31
0,05 %	Royal London Asset Management Ltd.	3 208 000	0	2023-12-31
0,05 %	JPMorgan Asset Management (Asia Pacific) Limited	3 072 000	354 000	2024-02-29
0,05 %	Royal London Asset Management (CIS) Limited_NLE	2 782 000	0	2023-08-31
0,04 %	CPP Investment Board	2 593 000	2 593 000	2023-03-31
0,04 %	INVESCO Asset Management Limited	2 564 000	−4 000	2023-12-31
0,04 %	Essence Fund Management Co., Ltd.	2 454 000	2 444 000	2023-12-31
0,04 %	Aviva Investors Global Services Limited	2 089 778	−212 884	2024-02-29
0,03 %	Credit Suisse Funds AG	2 064 000	54 000	2024-03-31
0,03 %	China Universal Asset Management Co., Ltd.	1 868 000	678 000	2023-12-31
0,03 %	Nuveen LLC	1 803 582	1 162	2024-03-31
0,03 %	Amundi Japan Ltd.	1 750 000	−24 000	2024-03-31
0,03 %	BlackRock (Singapore) Limited	1 721 321	427 474	2024-03-31
0,03 %	China Asset Management (Hong Kong) Limited	1 578 505	−83 236	2024-03-31
0,03 %	State Street Global Advisors (US)	1 554 087	−50 000	2024-03-31
0,03 %	DWS Investment GmbH	1 540 144	37 391	2024-03-31
0,03 %	CSOP Asset Management Limited	1 488 729	31 703	2024-03-31
0,03 %	Harvest Fund Management Co., Ltd.	1 486 000	252 000	2023-12-31
0,02 %	State Street Global Advisors (UK) Ltd.	1 437 980	2	2024-03-31
0,02 %	DWS Investments UK Limited	1 437 610	23 085	2024-03-31
0,02 %	Charles Schwab Investment Management, Inc.	1 267 724	0	2024-03-31
0,02 %	Penghua Fund Management Co., Ltd.	1 262 000	200 000	2023-12-31
0,02 %	Mirae Asset Global Investments (Hong Kong) Limited	1 122 286	241 242	2024-03-31
0,02 %	HSBC Global Asset Management (UK) Limited	1 081 556	−57 563	2024-02-29
0,02 %	Storebrand Kapitalforvaltning AS	1 054 602	26 000	2024-02-29
0,02 %	BlackRock Investment Management (UK) Ltd.	1 052 000	−74 000	2024-02-29
0,02 %	Handelsbanken Kapitalförvaltning AB	1 008 000	72 000	2024-03-31
0,02 %	Fullgoal Fund Management Co., Ltd.	972 000	742 000	2023-12-31
0,02 %	Lyu (Aifeng)	955 500	90 000	2023-06-15
0,02 %	KLP Fondsforvaltning AS	934 000	0	2024-02-29
0,02 %	GAM International Management Ltd.	900 000	0	2024-02-29
0,01 %	UBS Asset Management (Switzerland)	888 000	0	2024-02-29
0,01 %	Irish Life Investment Managers Ltd.	860 900	−3 100	2024-03-31
0,01 %	PGGM Vermogensbeheer B.V.	859 328	3 043	2023-07-31
0,01 %	Bank of China Investment Management Co., Ltd.	856 000	620 000	2023-06-30
0,01 %	Goldman Sachs Advisors B.V._NLE	822 000	56 000	2023-11-30
0,01 %	Zürcher Kantonalbank (Asset Management)	780 480	220 000	2024-02-29
0,01 %	Mercer Global Investments Management Ltd	777 809	0	2024-03-31
0,01 %	China Southern Asset Management Co. Ltd.	760 000	228 000	2023-12-31
0,01 %	American Century Investment Management, Inc.	750 000	128 000	2024-03-31
0,01 %	Mellon Investments Corporation	738 100	122 000	2024-03-31
0,01 %	Dimensional Fund Advisors, Ltd.	704 000	0	2024-02-29
0,01 %	Lazard Asset Management, L.L.C.	696 000	0	2023-12-31
0,01 %	Baoying Fund Management Co., Ltd.	622 719	622 719	2023-12-31
0,01 %	BOCI-Prudential Asset Management Ltd.	586 744	0	2024-02-29
0,01 %	Robeco Institutional Asset Management B.V.	544 000	390 000	2024-02-29
0,01 %	Legal & General Investment Management Ltd.	540 000	−64 000	2024-02-29
0,01 %	Northern Trust Investments, Inc.	530 000	−8 000	2024-03-31
0,01 %	Tianhong Asset Management Co., Ltd.	526 000	234 000	2023-12-31
0,01 %	Yinhua Fund Management Co., Ltd.	482 000	302 000	2023-12-31
0,01 %	British Columbia Investment Management Corp.	481 158	−15 539	2023-03-31
0,01 %	Cardano Asset Management NV	475 137	55	2024-02-29
0,01 %	GAM (Luxembourg) S.A.	450 000	−100 000	2024-02-29
0,01 %	California State Teachers Retirement System	442 000	−90 000	2023-06-30
0,01 %	Swedbank Robur Fonder AB	424 000	−22 000	2024-02-29
0,01 %	BMO Asset Management Inc.	419 440	0	2024-03-31
0,01 %	Sun (Yuan)	408 100	408 100	2023-04-29
0,01 %	Maxwealth Fund Management Co., Ltd.	400 000	400 000	2023-06-30
0,01 %	Bellevue Asset Management AG	400 000	100 000	2024-02-29
0,01 %	Eurizon Capital S.A.	386 393	6 254	2024-02-29
0,01 %	Hony Horizon Fund Management Co., Ltd.	386 000	386 000	2023-12-31
0,01 %	Mirae Asset Global Investments (USA) LLC	347 943	6 000	2024-03-31
0,01 %	Hwabao WP Fund Management Co., Ltd.	340 000	154 000	2023-12-31
0,01 %	Morgan Stanley Investment Management (China) Company Limited.	338 000	338 000	2023-12-31
0,01 %	Krane Funds Advisors, LLC	336 000	0	2024-03-31
0,01 %	UBS Asset Management Switzerland AG	334 000	0	2024-02-29
0,01 %	Nykredit Bank AS	326 000	86 000	2024-02-29
0,01 %	Vestcor Inc	314 081	−158 824	2022-12-31
0,01 %	Guliver Anlageberatung GmbH	306 000	64 000	2024-01-31
0,00 %	Vanguard Investments Australia Ltd.	295 611	151	2024-02-29
0,00 %	OP Varainhoito Oy	286 000	0	2024-02-29
0,00 %	Huatai-PineBridge Fund Management Co., Ltd.	268 630	20 000	2023-12-31
0,00 %	Degroof Petercam Asset Management	262 269	0	2023-12-31
0,00 %	Oberweis Asset Management, Inc.	250 000	250 000	2023-12-31

What values and corporate philosophy does Hansoh Pharmaceutical Group Company represent?

Hansoh Pharmaceutical Group Co Ltd represents values of innovation, quality, and patient-centricity. With a strong corporate philosophy, the company focuses on developing and delivering high-quality pharmaceutical products that improve and save lives. Hansoh Pharmaceutical Group Co Ltd's commitment to innovation drives the development of new and effective therapies to address unmet medical needs. The company's patient-centric approach ensures that their products are developed and manufactured with the highest quality standards, aiming to provide optimal healthcare solutions for patients worldwide. Hansoh Pharmaceutical Group Co Ltd's dedication to excellence makes them a trusted and reliable player in the pharmaceutical industry.

In which countries and regions is Hansoh Pharmaceutical Group Company primarily present?

Hansoh Pharmaceutical Group Co Ltd is primarily present in China.

What significant milestones has the company Hansoh Pharmaceutical Group Company achieved?

Hansoh Pharmaceutical Group Co Ltd has achieved several significant milestones. In recent years, the company successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange, marking a major milestone in its financial development. Additionally, Hansoh Pharmaceutical Group has made significant advancements in its research and development efforts, resulting in the successful launch of innovative and high-quality pharmaceutical products. The company has also expanded its global footprint by establishing strategic collaborations and partnerships with international pharmaceutical companies. Overall, Hansoh Pharmaceutical Group Co Ltd continues to make notable strides in the pharmaceutical industry, solidifying its position as a leading player in the market.

What is the history and background of the company Hansoh Pharmaceutical Group Company?

Hansoh Pharmaceutical Group Co Ltd is a leading pharmaceutical company with a rich history and background. Founded in 1995, the company has rapidly grown to become one of the largest and most respected pharmaceutical companies in China. Hansoh Pharmaceutical focuses on the research, development, manufacturing, and commercialization of innovative drugs in various therapeutic areas like oncology, diabetes, and cardiovascular diseases. With a strong emphasis on innovation and quality, Hansoh Pharmaceutical has successfully introduced numerous blockbuster drugs, gaining recognition both domestically and internationally. The company's commitment to excellence and patient care has established it as a trusted name in the pharmaceutical industry.

Who are the main competitors of Hansoh Pharmaceutical Group Company in the market?

The main competitors of Hansoh Pharmaceutical Group Co Ltd in the market include well-known pharmaceutical companies such as Shanghai Pharmaceuticals Holding Co Ltd, Jiangsu Hengrui Medicine Co Ltd, and Sino Biopharmaceutical Ltd. These companies compete with Hansoh Pharmaceutical Group Co Ltd in terms of research and development, product portfolio, market presence, and overall performance in the pharmaceutical industry.

In which industries is Hansoh Pharmaceutical Group Company primarily active?

Hansoh Pharmaceutical Group Co Ltd primarily operates in the pharmaceutical industry.

What is the business model of Hansoh Pharmaceutical Group Company?

The business model of Hansoh Pharmaceutical Group Co Ltd is focused on research, development, manufacturing, and commercialization of innovative pharmaceutical products. As one of the leading pharmaceutical companies in China, Hansoh Pharmaceutical Group Co Ltd aims to provide high-quality and affordable medications to improve the well-being of individuals. The company collaborates with healthcare professionals and institutions to meet the evolving healthcare needs of patients. Hansoh Pharmaceutical Group Co Ltd's business model emphasizes continuous innovation, leveraging cutting-edge technology, and maintaining strong partnerships across the industry. Through its diversified portfolio and commitment to excellence, the company strives to contribute to the advancement of healthcare in China and globally.

Koks yra Hansoh Pharmaceutical Group Company 2024 KGV?

Hansoh Pharmaceutical Group Company KGV yra 26,60.

Koks Hansoh Pharmaceutical Group Company 2024 KUV?

Hansoh Pharmaceutical Group Company KUV yra 8,28.

Koks yra Hansoh Pharmaceutical Group Company AlleAktien kokybės įvertinimas?

AlleAktien kokybės įvertis Hansoh Pharmaceutical Group Company yra 3/10.

Koks yra Hansoh Pharmaceutical Group Company 2024 pajamų dydis?

tikėtina Hansoh Pharmaceutical Group Company pardavimai yra 12,10 mlrd. CNY.

Kokia yra Hansoh Pharmaceutical Group Company 2024 pelnas?

tikėtina Hansoh Pharmaceutical Group Company pelnas yra 3,77 mlrd. CNY.

Ką daro Hansoh Pharmaceutical Group Company?

Hansoh Pharmaceutical Group Co Ltd is a leading Chinese pharmaceutical company specializing in research, development, production, and distribution of innovative and generic drugs. The company originated in Jiangsu province, China and operates globally today. The business model of Hansoh consists of various divisions focusing on drug development, manufacturing, distribution, and marketing. The company has a strong presence in the Asian market and is expanding its business worldwide. The divisions of Hansoh include research and development of new drugs, generics, over-the-counter products, and biological drugs. The company is renowned for its capabilities in active ingredient research, development, and manufacturing. Hansoh's products cover a wide range of therapeutic areas including oncology, cardiology, neurology, and infectious diseases. In the research and development field, Hansoh drives growth through investments in cutting-edge technologies like new drug research in collaboration with universities and research institutes, artificial intelligence and big data, as well as close cooperation with other companies. The generics division is a crucial part of Hansoh's business model. The company offers a wide range of generics, providing a cost-effective yet effective alternative to expensive brand-name products. The company works towards lowering production costs in the long term and facilitating access to medication for patients worldwide. Additionally, the company operates in the over-the-counter (OTC) sector, offering products such as vitamins, pain relievers, and non-prescription medications. Hansoh also focuses heavily on biological drugs, particularly in the field of antibody therapy. Here, the company works on developing new drugs for the treatment of cancer and other serious illnesses. To make Hansoh Pharma's business successful, the company has established a strong presence in key markets around the world. Collaboration with other pharmaceutical companies to jointly market and distribute their products is a crucial aspect. For example, Germany and the USA are important markets for the company. Overall, the business model of Hansoh Pharmaceutical Group Co Ltd is focused on the long-term sustainability and growth of their business. Through a combination of innovative development and production processes, a broad portfolio of drugs, and a strong presence in key markets worldwide, the company remains on a growth trajectory and will establish itself as a significant player in the global pharmaceutical industry in the future.

Kokia yra Hansoh Pharmaceutical Group Company dividendė?

Hansoh Pharmaceutical Group Company moka dividendą 0,23 CNY, kuris yra paskirstytas per išmokas per metus.

Kiek kartų Hansoh Pharmaceutical Group Company moka dividendą?

Dividenda šiuo metu negali būti apskaičiuota Hansoh Pharmaceutical Group Company arba įmonė dividendų nemoka.

Kas yra Hansoh Pharmaceutical Group Company ISIN?

Hansoh Pharmaceutical Group Company ISIN yra KYG549581067.

Kas yra Hansoh Pharmaceutical Group Company WKN?

Hansoh Pharmaceutical Group Company WKN yra A2PLRC.

Kas yra Hansoh Pharmaceutical Group Company Tickeris?

Hansoh Pharmaceutical Group Company akcijų simbolis yra 3692.HK.

Kiek dividendų moka Hansoh Pharmaceutical Group Company?

Per paskutinius 12 mėnesių Hansoh Pharmaceutical Group Company išmokėjo dividendą, kurios dydis siekė 0,19 CNY . Tai atitinka maždaug 1,15 % dividendų grąžą. Artimiausiems 12 mėnesiams Hansoh Pharmaceutical Group Company tikėtina išmokės dividendus, kurie sudarys 0,20 CNY.

Kokia yra Hansoh Pharmaceutical Group Company dividendų grąža?

Hansoh Pharmaceutical Group Company šiuo metu yra 1,15 % dydžio dividendų grąža.

Kada Hansoh Pharmaceutical Group Company moka dividendus?

Hansoh Pharmaceutical Group Company moka dividendus kas ketvirtį. Jie išmokami spalis, liepa, spalis, liepa mėnesiais.

Kokia saugi yra Hansoh Pharmaceutical Group Company dividendų išmokėjimas?

Hansoh Pharmaceutical Group Company per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Kokia yra Hansoh Pharmaceutical Group Company dividendų suma?

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0,20 CNY. Tai atitinka 1,23 % dividendų grąžos procentą.

Kokiame sektoriuje yra Hansoh Pharmaceutical Group Company?

Hansoh Pharmaceutical Group Company priskiriamas sektoriui "Sveikata".

Wann musste ich die Aktien von Hansoh Pharmaceutical Group Company kaufen, um die vorherige Dividende zu erhalten?

Norėdamas gauti paskutinį Hansoh Pharmaceutical Group Company dividendą nuo 2024-07-17, kurio dydis yra 0,142 CNY, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2024-06-19.

Kada Hansoh Pharmaceutical Group Company paskutinį kartą mokėjo dividendą?

Paskutinės dividendų išmokėjimas įvyko 2024-07-17.

Kokia buvo Hansoh Pharmaceutical Group Company dividendų suma 2023 metais?

2023 metais Hansoh Pharmaceutical Group Company išmokėjo 0,23 CNY dividendų.

Kokia valiuta Hansoh Pharmaceutical Group Company moka dividendus?

Hansoh Pharmaceutical Group Company dividendai yra mokami CNY.

Tiesioginiai išleidimai	9 024,6
Netiesioginės emisijos iš įsigytos energijos	77 719,97
Tiesioginiai išmetimai iš vertybių grandinės	—
CO₂ emisijos	86 744,57
CO₂ mažinimo strategija	✅
Anglies energija	❌
Atomkraft	❌
Bandymai su gyvūnais	❌
Pelz & Leder	—
Pesticidai	—
Palmių aliejus	—
Tabakas	❌
Genetinė inžinerija	❌
Klimato koncepcija	—
Tvarioji miškininkystė	—
Perdirbimo nuostatai	✅
Aplinkai draugiška pakuotė	✅
Pavojingosios medžiagos	✅
Degalų sąnaudos ir efektyvumas	✅
Vandens suvartojimas ir efektyvumas	✅

Moterų dalis tarp darbuotojų	35,769
Moterų dalis valdyme	—
Azijietiškų darbuotojų dalis	—
Akcijų dalis Azijos valdyme	—
Hispanų/lotynų kilmės darbuotojų dalis	—
Hispanų/latino kilmės vadybos dalis	—
Akcijų turimų tamsios odos darbuotojų procentas	—
Juodaodžių valdymo dalis	—
Baltųjų darbuotojų dalis	—
Baltųjų valdymo dalis	—
Suaugusiųjų turinys	❌
Alkoholis	❌
Ginkluotė	—
Šaunamieji ginklai	❌
Azartiniai lošimai	❌
Karinių sutarčių	❌
Žmogaus teisių koncepcija	✅
Privatumo politika	—
Darbo ir sveikatos apsauga	✅
Katalikiškas	✅

Tvarumo ataskaita	✅
Akcijų turėtojų įtraukimas	✅
Atsiliepimo taisyklės	❌
Kartelio teisė	❌

Birža	Hansoh Pharmaceutical Group Company Akcijų kodas
FRANKFURTAS	3KY.F
HKSE	3692.HK
MIUNCHENAS	3KY.MU

Hansoh Pharmaceutical Group Company Akcijų kodas	Hansoh Pharmaceutical Group Company FIGI
3692:HK	BBG00P78Y7N1
3692EUR:XS	BBG00PG9MD40
3692EUR:XH	BBG00PG9MD77
3692EUR:XF	BBG00PG9MD95
3692EUR:XE	BBG00PG9MDC1
3692EUR:XJ	BBG00PG9MDD0
3692EUR:XL	BBG00PG9MDF8
3692EUR:XG	BBG00PG9MDG7
3692EUR:XO	BBG00PG9MDH6
3692EUR:XA	BBG00PG9MDM0
3692EUR:E1	BBG00PG9MDN9
3692EUR:XT	BBG00PG9MDP7
3692EUR:XW	BBG00PG9MDQ6
3692EUR:XU	BBG00PG9MDR5
3692EUR:XV	BBG00PG9MDS4
3692EUR:XM	BBG00PG9MDT3
3692EUR:XQ	BBG00PG9MDV0
3692EUR:XX	BBG00PG9MDW9
3692EUR:XZ	BBG00PG9MDX8
3692EUR:EU	BBG00PG9MDZ6
3KY:TH	BBG00PGKL8X5
3KY:GR	BBG00PGLT3M8
3KY:GF	BBG00PGLT3N7
3KY:GS	BBG00PGLT3R3
3KY:GM	BBG00PGLT3S2
3692HKD:EP	BBG00PH03PP9
3692HKD:EZ	BBG00PH03PR7
3692HKD:XS	BBG00PH03PS6
3692HKD:XH	BBG00PH03PW1
3692HKD:XF	BBG00PH03PY9
3692HKD:XE	BBG00PH03Q04
3692HKD:XJ	BBG00PH03Q13
3692HKD:XL	BBG00PH03Q22
3692HKD:XG	BBG00PH03Q31
3692HKD:XO	BBG00PH03Q40
3692HKD:XA	BBG00PH03Q86
3692HKD:E1	BBG00PH03Q95
3692HKD:XT	BBG00PH03QB2
3692HKD:XW	BBG00PH03QC1
3692HKD:XU	BBG00PH03QD0
3692HKD:XV	BBG00PH03QF8
3692HKD:XM	BBG00PH03QG7
3692HKD:XQ	BBG00PH03QH6
3692HKD:XX	BBG00PH03QJ4
3692HKD:XZ	BBG00PH03QK2
3692HKD:EU	BBG00PH03QN9
3692:H1	BBG00Q6WB3D2
3692:H2	BBG00Q6WBGD3
3KY:GZ	BBG00W9LMHM7
3692EUR:EP	BBG00W9LR9N9
3692EUR:EZ	BBG00W9LR9Q6
HNSPF:US	BBG00Z8393Z3
HNSPF:PQ	BBG00Z8394D5
HNSPF:UV	BBG00Z8394F3
3KY:LA	BBG018H9RRP7
3KY:LU	BBG018J3F9G1

Padaryk geriausias savo gyvenimo investicijas

Kursas

Akcijos kaina

Akcijų kodas3692.HK

ISINKYG549581067

VVPA2PLRC

Hansoh Pharmaceutical Group Company akcijų apyvarta, EBIT, pelnas KYG549581067 · A2PLRC

Pajamos, pelnas & EBIT

Supratimas apie pajamas, EBIT ir pelną

Metinė analizė ir palyginimai

Išnaudoti lūkesčius investuojant

Investicijų įžvalgos

Hansoh Pharmaceutical Group Company Pajamų, pelno ir EBIT istorija.

Hansoh Pharmaceutical Group Company Akcijų rodikliai

GuV

Pajamos ir augimas

Bruto marža

EBIT ir EBIT marža

Pajamos ir jų augimas

Leidžiamų akcijų skaičius

Metinių duomenų palyginimo interpretacija

Lūkesčiai ir prognozės

Balansas

Balanso supratimas

Turtas

Įsipareigojimai

Nuosavas kapitalas

Metų po metų analizė

Duomenų interpretacija

Hansoh Pharmaceutical Group Company Akcijos Maržos KYG549581067 · A2PLRC

Margen

Supratimas apie bruto maržą

EBIT maržos analizė

Pardavimų maržos įžvalgos

Lūkesčių interpretavimas

Lyginamoji analizė

Hansoh Pharmaceutical Group Company Maržų istorija

Hansoh Pharmaceutical Group Company akcijos apyvarta, EBIT, pelnas vienai akcijai KYG549581067 · A2PLRC

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

Hansoh Pharmaceutical Group Company Pardavimų, pelno ir EBIT istorija vienai akcijai

Hansoh Pharmaceutical Group Company akcija ir akcijų analizė

Hansoh Pharmaceutical Group Company įvertinimas pagal istorinį P/E, EBIT ir P/S

Hansoh Pharmaceutical Group Company akcijų skaičius KYG549581067 · A2PLRC

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

Hansoh Pharmaceutical Group Company akcijos dividendas KYG549581067 · A2PLRC

Dividendas

Dividendų apžvalga

Interpretacija ir naudojimas

Investavimo strategija

Hansoh Pharmaceutical Group Company Dividendų istorija

Hansoh Pharmaceutical Group Company akcijų išmokėjimo koeficientas KYG549581067 · A2PLRC

Dividendų mokėjimo rodiklis

Kas yra metinis dividendų mokėjimo rodiklis?

Kaip interpretuoti duomenis

Duomenų naudojimas investavimui

Hansoh Pharmaceutical Group Company Dividendų išmokėjimo istorija

Hansoh Pharmaceutical Group Company Pelno prognozės

Hansoh Pharmaceutical Group Company Pelnų staigmenos

Eulerpool ESG reitingas Hansoh Pharmaceutical Group Company akcijai

Eulerpool World ESG Rating (EESG©)

82/ 100

🌱 Environment

👫 Social

🏛️ Governance

Aplinka (Environment)

Socialinis (Social)

Įmonės valdymas (Governance)

Hansoh Pharmaceutical Group Company akcijos akcininkų struktūra

Hansoh Pharmaceutical Group Company Valdyba ir Priežiūros taryba

Dažnai užduodami klausimai apie Hansoh Pharmaceutical Group Company akciją

What values and corporate philosophy does Hansoh Pharmaceutical Group Company represent?

In which countries and regions is Hansoh Pharmaceutical Group Company primarily present?

Akcijų kodas
3692.HK

ISIN
KYG549581067

VVP
A2PLRC